Company intelligence / Profile preview

Ebvia

San Francisco, California, United Statesebvia.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Ebvia is developing a novel outpatient treatment for breakthrough COVID‑19 infections. Their lead drug candidate demonstrated 100% survival in a highly lethal animal model of SARS-CoV‑2 infection, significantly reduced lung and brain pathology in mice, showed high potency against the Delta variant, and efficacy against multiple influenza strains. No human clinical trial results are reported yet

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (inferred from context; not explicitly stated but likely given the outpatient drug development focus)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of now.

Beyond the preview

Go deeper on Ebvia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebvia.

Explore the full profile